Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.48 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15614091 | 0.96 | ASIC3 (0.53) | ASIC3ADORA2AADORA1GRM4ALDH1A1 | |
| SCHEMBL15268979 | 0.84 | ALOX5AP (0.55) | ASIC3ADORA2AADORA1GRM4ALDH1A1 | |
| SCHEMBL13996075 | 0.84 | MEN1 (0.62) | ASIC3ADORA2AADORA1ALDH1A1MEN1 | |
| SCHEMBL23143338 | 0.83 | LMNA (0.42) | ASIC3ALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL3068958 | 0.82 | HSP90AA1 (0.56) | ALDH1A1MEN1RAB9AHSP90AA1MAPT | |
| SCHEMBL2252732 | 0.79 | ALDH1A1 (0.48) | ALDH1A1RAB9ACYP11B2KDM4EALOX5AP | |
| SCHEMBL3064277 | 0.77 | KDM4E (0.54) | ADORA2AMEN1KMT2ACYP11B2MAPT | |
| SCHEMBL15269260 | 0.75 | PDGFRB (0.54) | RAB9ANPC1ALOX5APFEN1 | |
| SCHEMBL21682820 | 0.75 | PIM1 (0.61) | ADORA2ACYP11B2CYP11B1ALOX5APFEN1 | |
| SCHEMBL13798848 | 0.74 | RAB9A (0.44) | ASIC3ADORA2AADORA1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066315-A1 | COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY LLC | 2023-03-02 | — | — | US | disclosed |
| US-20220298142-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-09-22 | — | — | US | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2022-04-21 | — | — | US | disclosed |
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2022-04-19 | — | — | US | disclosed |
| EP-3670520-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE ORGANOMETALLIC COMPOUND, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND | SAMSUNG ELECTRONICS CO LTD (KR) | 2022-01-12 | — | — | EP | disclosed |
| CN-113924095-A | Heterocyclic compounds as adenosine antagonists | 诺维逊生物股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3911325-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911322-A1 | COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911323-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-1379510-B1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHEMOSENSITIZERS | ICOS CORP (US) | 2011-06-01 | — | — | EP | disclosed |
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | KEEGAN KATHLEEN S | 2010-04-29 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| CN-100374425-C | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | YILE LILY CO LTD (US) | 2008-03-12 | — | — | CN | disclosed |
| US-7067506-B2 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | ICOS CORPORATION (US) | 2005-11-03 | — | — | US | disclosed |
| CN-1507436-A | Aryl and heteroaryl urea CHK1 inhibitors for use as radiosensitizers and chamosensitizers | — | 2004-06-23 | — | — | CN | disclosed |
| EP-1379510-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | ICOS CORPORATION (A WASHINGTON CORPORATION) | 2003-04-10 | — | — | US | disclosed |
| WO-2002070494-A1 | ARYL AND HETEROARYL UREA CHK1 INHIBITORS FOR USE AS RADIOSENSITIZERS AND CHAMOSENSITIZERS | ICOS CORPORATION (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105683-A1 | COMPOUNDS USEFUL FOR INHIBITING CHK1 | CHEK1, PCNA, CHEK2 | ASIC3 4870/4885ADORA2A 4166/4885ADORA1 4468/4885 |
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | ASIC3 2783/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20050245525-A1 | Compounds useful for inhibiting CHK1 | CHEK1, PCNA, CHEK2 | ASIC3 4870/4885ADORA2A 4166/4885ADORA1 4468/4885 |
| US-20230066315-A1 | COMPOUNDS AND USES THEREOF | ADORA2A, GRK2, GRK4 | ASIC3 2708/4885ADORA2A 1/4885ADORA1 13/4885 |
| US-20220119367-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ASIC3 2799/4885ADORA2A 1/4885ADORA1 3/4885 |
| US-20030069284-A1 | Compounds useful for inhibiting Chk1 | CHEK1, PCNA, CHEK2 | ASIC3 4870/4885ADORA2A 4166/4885ADORA1 4468/4885 |
| US-20220298142-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ASIC3 2783/4885ADORA2A 1/4885ADORA1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.